Mauna Kea Technologies SA (1MK.F)
| Previous Close | 0.4005 |
| Open | 0.3980 |
| Bid | 0.4190 x 0 |
| Ask | 0.4600 x 0 |
| Day's Range | 0.3980 - 0.4400 |
| 52 Week Range | 0.3305 - 0.6750 |
| Volume | |
| Avg. Volume | 978 |
| Market Cap | 28.935M |
| Beta (5Y Monthly) | 1.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Mauna Kea Technologies Announces Results of Its Combined General Meeting of June 6, 2024
PARIS & BOSTON, June 07, 2024--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, held its Combined General Meeting of June 6, 2024, which was chaired by Mr. Sacha Loiseau, Chairman of the Board of Directors and CEO.
- Business Wire
Mauna Kea Technologies Announces Joint Venture in China Obtained Class II Medical Device Business License
PARIS & BOSTON, June 06, 2024--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that its joint venture with Tasly Pharmaceutical, Tasly Mauna Kea Medical Engineering Technology, has successfully obtained the Class II Medical Device Business License in China.
- Business Wire
Mauna Kea Technologies Winner of "Best New Technology Solution – Oncology" MedTech Breakthrough Award
PARIS & BOSTON, May 30, 2024--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that it has been selected as the winner of the "Best New Technology Solution - Oncology" award in the 8th annual MedTech Breakthrough Awards program. MedTech Breakthrough is an independent market intelligence organization that recognizes the top companies, technologies,
